37th BMCS Spring Symposium on Medicinal Chemistry
Event
37th BMCS Spring Symposium on Medicinal Chemistry
Dates
Thursday 23rd April, 2026
Place
The Fielder Centre, Hatfield, UK
Important links and downloads
Social Media – #HatfieldMedChem26
To submit your Abstract, click here
To register, click here
To Exhibit/Sponsor, click here
Synopsis
Known colloquially as the “Hatfield MedChem” meeting, this is a highly successful, long-standing, one-day meeting that runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics at the forefront of drug discovery. The meeting aims to be informal and interactive, and is ideal for all those working in medicinal chemistry and drug discovery more widely.
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC events, please follow this RSC link.
Registration
Please click here to register.
RSC Member: £150.00
Non-Member: £200.00
RSC Student Member: £75.00
Student Non-Member: £98.00
RSC Unemployed Member: £45.00
Unemployed Non-Member: £75.00
Retired Member: £45.00
Abstracts
Abstract submission for poster presentations is still open. Please click here to submit your abstract.
The deadline for oral abstract submission is Midnight GMT, Friday 28th November 2025.
The deadline for poster abstract submission is Midnight GMT, Friday 6th February 2026.
Sponsorship/Exhibition Opportunities
Opportunities to sponsor or exhibit at the meeting are now open, please click here to book.
*FULLY BOOKED* Exhibition stand package includes (£700):
– A table and chairs
– Access to electricity and wi-fi
– Logo inclusion in pdf of delegate handbook and rolling slides
– Promotional page in the pdf delegate handbook
– One stand personnel with access to technical sessions
Programme
| 9.00 | Registration and refreshments |
| 9.30 | Welcome and Introduction Douglas Williamson, Nxera Pharma |
| SESSION CHAIR: Katie Simmons, University of Leeds | |
| 9.35 | Simon Peace (GSK) Discovery of inhaled FRAP1 inhibitor GSK4003332 for the treatment of pulmonary fibrosis and its assessment via application of a novel safety strategy |
| 10.05 | Oscar Barba (Independent Drug Discovery Advisor, Sitryx) Discovery of Novel Phthalazinones as PKM2 Activators |
| 10.35 | Tea/Coffee, Posters and Exhibition |
| SESSION CHAIR: Nicole Hamblin | |
| 11.05 | Agostina Cianciulli (Evotec) GPR39 antagonism: A new paradigm for the treatment of Acute Myocardial Ischemia |
| 11.35 | Henrik Moebitz (Novartis) Nonclassical Zwitterions as a Design Principle to Reduce Lipophilicity without Impacting Permeability |
| 12.05 | Rachel Grainger (Astex) Next-generation Structure-Based Drug Design (SBDD) |
| 12.35 | Lunch, Posters and Exhibition |
| SESSION CHAIR: Alison Jones, Charles River | |
| 13.45 | Capps Green Zomaya Award Lecture |
| 14.15 | Jonathan Powell (Domainex) Development of C5aR1 negative allosteric modulators (NAMs) with potential benefits for neuroinflammation |
| 14.50 | Akane Kawamura |
| 15.20 | Tea/Coffee, Posters and Exhibition |
| 15.50 | Poster Prize |
| 15.55 | Mattia Cocco (AstraZeneca) Hemiasterlins: Navigating SAR for Antibody-Drug Conjugates in Cancer Therapy |
| 16.25 | Mark Andrews (Pharmaron UK) Identification of novel macrocyclic inhibitors of the polymerase domain of DNA polymerase theta |
| 16.55 | Concluding remarks Adrian Hall, UCB |
| 17.00 | Meeting close |
Confirmed Exhibitors
 |  |  |
|---|---|---|
 |  |  |
 |  |  |
 |  |  |
 |  |  |
Confirmed Sponsors
Confirmed Speakers
Agostino Cianciulli, Evotec
GPR39 antagonism: A new paradigm for the treatment of Acute Myocardial Ischemia
Mark Andrews, Pharmaron
Identification of novel macrocyclic inhibitors of the polymerase domain of DNA polymerase theta
Mattia Cocco, AstraZeneca
Hemiasterlins: Navigating SAR for Antibody-Drug Conjugates in Cancer Therapy
Oscar Barba, Independent Drug Discovery Advisor, Sitryx
Discovery of Novel Phthalazinones as PKM2 Activators
Simon Peace, GSK
Discovery of inhaled FRAP1 inhibitor GSK4003332 for the treatment of pulmonary fibrosis and its assessment via application of a novel safety strategy
Rachel Grainger, Astex
Capps Green Zomaya Lecture
Organising Committee
Adrian Hall, UCB (Chair)
Douglas Williamson, Nxera Pharma (Treasurer)
David Hirst, Tessellate Bio
Alison Jones, Charles River
Secretariat Contact and Further Information
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail
